Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | Journal Article | ||||||||||||
PMID | (23680147) | ||||||||||||
Authors | Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, Janakiraman V, Scholz RP, Bowman KK, Lorenzo M, Li H, Wu J, Yuan W, Peters BA, Kan Z, Stinson J, Mak M, Modrusan Z, Eigenbrot C, Firestein R, Stern HM, Rajalingam K, Schaefer G, Merchant MA, Sliwkowski MX, de Sauvage FJ, Seshagiri S | ||||||||||||
Title | Oncogenic ERBB3 mutations in human cancers. | ||||||||||||
|
|||||||||||||
URL | |||||||||||||
Abstract Text | The human epidermal growth factor receptor (HER) family of tyrosine kinases is deregulated in multiple cancers either through amplification, overexpression, or mutation. ERBB3/HER3, the only member with an impaired kinase domain, although amplified or overexpressed in some cancers, has not been reported to carry oncogenic mutations. Here, we report the identification of ERBB3 somatic mutations in ~11% of colon and gastric cancers. We found that the ERBB3 mutants transformed colonic and breast epithelial cells in a ligand-independent manner. However, the mutant ERBB3 oncogenic activity was dependent on kinase-active ERBB2. Furthermore, we found that anti-ERBB antibodies and small molecule inhibitors effectively blocked mutant ERBB3-mediated oncogenic signaling and disease progression in vivo. |
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|---|---|---|---|---|
No data available in table |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
No data available in table |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
No data available in table |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|---|---|---|---|---|
ERBB3 | V104M | missense | unknown | ERBB3 (HER3) V104M lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). V104M results in phosphorylation of Akt and Erk, and transformation of Erbb2 (Her2)-expressing cells in culture (PMID: 23680147), however, V104M results in similar cell proliferation and viability levels as wild-type Erbb3 (Her3) in another study (PMID: 29533785), and therefore, its effect on Erbb3 (Her3) protein function is unknown. | |
ERBB3 | A232V | missense | gain of function | ERBB3 (HER3) A232V lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org, PMID: 23680147). A232V confers a gain of Erbb3 (Her3) protein function, resulting in phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2) expressing cells (PMID: 23680147). | |
ERBB3 | P262H | missense | gain of function | ERBB3 (HER3) P262H lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). P262H confers a gain of Erbb3 (Her3) protein function, resulting in phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2) expressing cells (PMID: 23680147). | |
ERBB3 | G284R | missense | unknown | ERBB3 (HER3) G284R lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). G284R results in increased phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2)-expressing cells relative to wild-type Erbb3 (Her3) (PMID: 23680147) and leads to increased cell proliferation in Erbb2 (Her2)-overexpressing cells in culture (PMID: 29963236), but has not been individually characterized and therefore, its effect on Erbb3 (Her3) protein function is unknown. | |
ERBB3 | T389K | missense | gain of function | ERBB3 (HER3) T389K lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). T389K confers a gain of Erbb3 (Her3) protein function, resulting in phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2) expressing cells (PMID: 23680147). | |
ERBB3 | V714M | missense | no effect | ERBB3 (HER3) V714M lies within the protein kinase domain of the Erbb3 (Her3) protein (UniProt.org). V714M demonstrates growth promotion and transforming ability in the presence of Erbb2 (Her2) similar to wild-type Erbb3 (Her3) in culture (PMID: 23680147). | |
ERBB3 | Q809R | missense | gain of function | ERBB3 (HER3) Q809R lies within the protein kinase domain of the Erbb3 (Her3) protein (UniProt.org). Q809R confers a gain of Erbb3 (Her3) protein function, resulting in phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2) expressing cells (PMID: 23680147). | |
ERBB3 | S846I | missense | gain of function | ERBB3 (HER3) S846I lies within the protein kinase domain of the Erbb3 (Her3) protein (UniProt.org). S846I confers a gain of Erbb3 (Her3) protein function, resulting in phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2) expressing cells (PMID: 23680147). | |
ERBB3 | E928G | missense | gain of function | ERBB3 (HER3) E928G lies within the protein kinase domain of the Erbb3 (Her3) protein (UniProt.org). E928G confers a gain of Erbb3 (Her3) protein function, resulting in phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2) expressing cells (PMID: 23680147) and increased IL3-independent growth upon co-expression with ERBB2 (HER2) V956R, an impaired activator of homodimerization, in culture (PMID: 38806620). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB3 A232V | Advanced Solid Tumor | sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) A232V in culture (PMID: 23680147). | 23680147 |
ERBB3 A232V | Advanced Solid Tumor | sensitive | Pictilisib | Preclinical - Cell culture | Actionable | In a preclinical study, Pictilisib (GDC-0941) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) A232V in culture (PMID: 23680147). | 23680147 |
ERBB3 A232V | Advanced Solid Tumor | sensitive | Pertuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, Perjeta (pertuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) A232V in culture (PMID: 23680147). | 23680147 |
ERBB3 act mut | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) activating mutations (PMID: 23680147). | 23680147 |
ERBB3 T389K | Advanced Solid Tumor | sensitive | Pertuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, Perjeta (pertuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) T389K in culture (PMID: 23680147). | 23680147 |
ERBB3 T389K | Advanced Solid Tumor | sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) T389K in culture (PMID: 23680147). | 23680147 |
ERBB3 T389K | Advanced Solid Tumor | sensitive | Pictilisib | Preclinical - Cell culture | Actionable | In a preclinical study, Pictilisib (GDC-0941) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) T389K in culture (PMID: 23680147). | 23680147 |
ERBB3 V104M | Advanced Solid Tumor | sensitive | Pictilisib | Preclinical - Cell culture | Actionable | In a preclinical study, Pictilisib (GDC-0941) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V104M in culture (PMID: 23680147). | 23680147 |
ERBB3 V104M | Advanced Solid Tumor | sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V104M in culture (PMID: 23680147). | 23680147 |
ERBB3 V104M | Advanced Solid Tumor | sensitive | Pertuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, Perjeta (pertuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V104M in culture (PMID: 23680147). | 23680147 |
ERBB3 V714M | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V714M in culture (PMID: 23680147). | 23680147 |
ERBB3 V714M | Advanced Solid Tumor | sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V714M in culture (PMID: 23680147). | 23680147 |
ERBB3 V714M | Advanced Solid Tumor | sensitive | Pertuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, Perjeta (pertuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V714M in culture (PMID: 23680147). | 23680147 |
ERBB3 A232V | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) A232V (PMID: 23680147). | 23680147 |
ERBB3 G284R | Advanced Solid Tumor | sensitive | Duligotuzumab | Preclinical | Actionable | In a preclinical study, MEHD7945A inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). | 23680147 |
ERBB3 G284R | Advanced Solid Tumor | sensitive | Mirdametinib + Pictilisib | Preclinical | Actionable | In a preclinical study, the combination of GDC-0941 and Gomekli (mirdametinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). | 23680147 |
ERBB3 G284R | Advanced Solid Tumor | sensitive | Pictilisib | Preclinical | Actionable | In a preclinical study, the PI3K inhibitor GDC-0941 inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). | 23680147 |
ERBB3 G284R | Advanced Solid Tumor | resistant | Cetuximab | Preclinical | Actionable | In a preclinical study, transformed cell lines expressing ERBB3 (HER3) G284R demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 23680147). | 23680147 |
ERBB3 G284R | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). | 23680147 |
ERBB3 G284R | Advanced Solid Tumor | sensitive | Pertuzumab | Preclinical | Actionable | In a preclinical study, Perjeta (pertuzumab) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). | 23680147 |
ERBB3 G284R | Advanced Solid Tumor | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). | 23680147 |
ERBB3 P262H | Advanced Solid Tumor | sensitive | Pictilisib | Preclinical | Actionable | In a preclinical study, the PI3K inhibitor GDC-0941 inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 |
ERBB3 P262H | Advanced Solid Tumor | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 |
ERBB3 P262H | Advanced Solid Tumor | sensitive | Pertuzumab | Preclinical | Actionable | In a preclinical study, Perjeta (pertuzumab) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 |
ERBB3 P262H | Advanced Solid Tumor | sensitive | Mirdametinib + Pictilisib | Preclinical | Actionable | In a preclinical study, the combination of GDC-0941 and Gomekli (mirdametinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 |
ERBB3 P262H | Advanced Solid Tumor | sensitive | Duligotuzumab | Preclinical | Actionable | In a preclinical study, MEHD7945A inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 |
ERBB3 P262H | Advanced Solid Tumor | resistant | Cetuximab | Preclinical | Actionable | In a preclinical study, transformed cell lines expressing ERBB3 (HER3) P262H demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 23680147). | 23680147 |
ERBB3 P262H | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 |
ERBB3 Q809R | Advanced Solid Tumor | sensitive | Duligotuzumab | Preclinical | Actionable | In a preclinical study, MEHD7945A inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147). | 23680147 |
ERBB3 Q809R | Advanced Solid Tumor | decreased response | Pertuzumab | Preclinical | Actionable | In a preclinical study, transformed cell lines expressing ERBB3 (HER3) Q809R in culture demonstrated a decreased response to Perjeta (pertuzumab), showing inhibition of proliferation and colony formation, but to a lesser degree than other therapies (PMID: 23680147). | 23680147 |
ERBB3 Q809R | Advanced Solid Tumor | decreased response | Pictilisib | Preclinical | Actionable | In a preclinical study, transformed cell lines expressing ERBB3 (HER3) Q809R in culture demonstrated a decreased response to Pictlisib (GDC-0941), showing inhibition of proliferation and colony formation, but to a lesser degree than other therapies (PMID: 23680147). | 23680147 |
ERBB3 Q809R | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147). | 23680147 |
ERBB3 Q809R | Advanced Solid Tumor | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147). | 23680147 |
ERBB3 Q809R | Advanced Solid Tumor | resistant | Cetuximab | Preclinical | Actionable | In a preclinical study, transformed cell lines expressing ERBB3 (HER3) Q809R demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 23680147). | 23680147 |
ERBB3 Q809R | Advanced Solid Tumor | sensitive | Mirdametinib + Pictilisib | Preclinical | Actionable | In a preclinical study, the combination of GDC-0941 and Gomekli (mirdametinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147). | 23680147 |
ERBB3 T389K | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) T389K (PMID: 23680147). | 23680147 |
ERBB3 V104M | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) V104M (PMID: 23680147). | 23680147 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: